AB Science S.A. (OTCMKTS:ABSCF) Short Interest Update

AB Science S.A. (OTCMKTS:ABSCF) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 500 shares, a decline of 66.7% from the January 15th total of 1,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

AB Science Price Performance

Shares of OTCMKTS ABSCF remained flat at $0.90 during midday trading on Wednesday. The stock’s 50-day moving average price is $0.90 and its two-hundred day moving average price is $1.01. AB Science has a 52 week low of $0.80 and a 52 week high of $1.06.

AB Science Company Profile

AB Science SA, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.